Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Daratumumab: First Global Approval

McKeage, Kate · 2016 · Drugs

Abstract

Daratumumab (Darzalex™) is a first-in-class, humanized IgG1κ monoclonal antibody that targets the CD38 epitope and was developed by Janssen Biotech and Genmab. Intravenous daratumumab was recently approved via an accelerated approval programme in the USA for patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. The drug is in preregistration for this indication in the EU and Canada. In a phase II trial in patients with previously treated (as described above) relapsed or refractory multiple myeloma, monotherapy with daratumumab 16 mg/kg achieved an overall response rate of approximately 30 %. This article summarizes the milestones in the development of daratumumab leading to this first approval for multiple myeloma.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-015-0536-1

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Research works printed but not linked: 3

  1. Genmab. US FDA grants priority review for daratumumab for double refractory multiple myeloma [media release]. http://ir.genmab.com/releasedetail.cfm?ReleaseID=930345 . Accessed 17 Dec 2015.
  2. Janssen. Janssen’s new drug submission for daratumumab for treatment of multiple myeloma accepted for review by Health Canada [media release]. https://www.janssen.com/canada/sites/www_janssen_com_canada/files/daratumumab_filing_news_release.pdf . Accessed 17 Dec 2015.
  3. Doshi P, Sasser AK, Axel A, et al. Daratumumab treatment in combination with CHOP or R-CHOP results in the inhibition or regression of tumors in preclinical models of non-hodgkins lymphoma [abstract no. P434]. Haematologica. 2014;99(Suppl 1):138–9.

Cited by

See all 126

Metadata

Authors
McKeage, K.
Corresponding author
McKeage, Kate
Venue
Drugs
Published
2016-01-04
Volume
76
Issue
2
Pages
275-281
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W2227353206
Cited by
120
References
16
Citations by year
2026: 5 · 2025: 7 · 2024: 12 · 2023: 8 · 2022: 14 · 2021: 13 · 2020: 14 · 2019: 12 · 2018: 12 · 2017: 13 · 2016: 10
FWCI
14.89
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
daratumumab, CD38, multiple myeloma, monoclonal antibodies, accelerated approval, relapsed/refractory multiple myeloma, drug development, regulatory approval
MeSH terms
Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma, Clinical Trials, Phase II as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Daratumumab: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-015-0536-1
The paper
McKeage, K. (2016). Daratumumab: First Global Approval. Drugs. https://doi.org/10.1007/s40265-015-0536-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.